Status and phase
Conditions
Treatments
About
A prospective, multicenter, open label, randomized phase III study to evaluate efficacy and safety of FFX versus CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically or cytologically confirmed metastatic Stage IV adenocarcinoma of the pancreas
No prior treatments for stage IV pancreatic adenocarcinoma (prior adjuvant or neoadjuvant treatment is allowed provided completed > 6 months prior to disease recurrence)
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
Male and female patients 18 - 75 years of age
Measurable disease determined using guidelines of Response Evaluation Criteria In Solid Tumors (RECIST version 1.1)
Expected survival >3 months
Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted highly effective contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive(s), intrauterine hormone releasing system (IUS), bilateral tubal occlusion or vasectomized partner) during and for 6 months after last study dose and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation, at monthly interval (day 1 of every even numbered cycle), at the end of systemic exposure, and at 30 days after the systemic exposure
Males with female partners (of childbearing potential) and female partners (of child bearing potential) with male partners must agree to use double barrier contraceptive measure (a combination of male condom with either cap, diaphragm or sponge with spermicide) in addition to oral contraception or avoidance of intercourse during the study and for 6 months after last study dose is received
At least 2 weeks must have elapsed from any prior surgery with resolution of any sequela for randomization
Laboratory values ≤2 weeks prior to randomization must be:
Adequate hematologic values
Adequate hepatic function
Adequate renal function serum creatinine clearance CLcr > 30 mL/min). (Cocroft-Gault Formula should be used for CrCl calculation)
Adequate coagulation function • International Normalized Ratio or INR must be <1.5 unless on therapeutic blood thinners)
No evidence of active infection and no serious infection within the past 30 days.
Mentally competent, ability to understand and willingness to sign the informed consent form.
Exclusion criteria
Folinic Acid
Fluorouracil/5FU
Oxaliplatin
Irinotecan
Primary purpose
Allocation
Interventional model
Masking
528 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal